Taficen

Quick links to important sections

Taficen

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Taficen

Quick Facts

Property Description
Active ingredient Terbinafine Hydrochloride
Form Oral Tablet, Topical Cream, Gel, Spray, or Solution
Pharmacological class Antifungal Agent, Allylamine derivative
General purpose Destroys fungal organisms
Origin Synthetic compound

What is Taficen and Its Active Component?

Taficen is a potent, synthetic compound classified as a pharmaceutical drug, focusing on the active ingredient Terbinafine Hydrochloride. This medication belongs to the Antifungal agent class, specifically categorized as an Allylamine derivative, a class pharmacologically recognized for its efficacy against dermatophytes and certain yeasts. As a single-ingredient product, Taficen's therapeutic action is driven by Terbinafine Hydrochloride, combined with necessary pharmaceutical excipients. This compound is characterized by its fungicidal action.


Taficen's Therapeutic Class and General Purpose

The general therapeutic purpose of Taficen is to address infections caused by various fungal organisms, serving as a primary antimycotic therapy. Its specific benefit is derived from its fungicidal action, which means it directly kills fungal cells rather than merely halting their growth. The mechanism of action interferes with the biosynthesis of fungal sterols, which are essential structural components, resulting in the elimination of the pathogen. This confirms that the medication actively destroys the fungal organism instead of just suppressing its growth.


Available Forms of Taficen for Administration

Taficen is designed for flexibility, allowing for both localized and internal use, determined by whether it is used systemically or topically. The available forms include Tablets for oral intake, intended for systemic coverage when the infection is deep or widespread, and topical preparations such as a cream, gel, spray, or solution, which are used for local application to the skin or nail surface. The availability of both systemic and topical preparations differentiates this drug, permitting selection of the most appropriate route of administration necessary to address the specific location and depth of the fungal condition.

Regulatory References

  1. Terbinafine - StatPearls - NCBI Bookshelf - NIH

What side effects are possible with Taficen?

Possible Side Effects and Safety Information

The safety profile of Taficen (Terbinafine Hydrochloride) is documented in regulatory sources by classifying possible effects based on frequency and the body system affected. Adverse reactions are grouped using System-Organ Classes to provide a structured overview of the drug's potential effects.


Frequency and System Classification

Adverse reactions are formally categorized based on observed frequency in clinical data and post-market experience:

  • Very Common (Affecting ge 1 in 10 persons): Includes headache, rash, urticaria, musculoskeletal reactions (joint and muscle pain), and certain gastrointestinal disorders such as dyspepsia and diarrhea.
  • Common (Affecting ge 1 in 100 to < 1 in 10 persons): Includes taste disturbance (potentially involving loss of taste), dizziness, and fatigue.

Observed effects span several System-Organ Classes, including the Gastrointestinal System, Hepato-biliary System, Skin and Subcutaneous Tissue, and Nervous System.


Serious Adverse Reactions and Constraints

Official labeling highlights the potential for Rare but clinically significant adverse reactions. These include severe hepatic reactions, such as liver failure and hepatitis, and serious skin conditions, like Stevens-Johnson syndrome. Severe hematological disorders, such as neutropenia and pancytopenia, are also documented.

The systemic use of Taficen is subject to specific safety constraints. It is generally contraindicated or not recommended for individuals with pre-existing chronic or active hepatic impairment. Furthermore, the safety profile notes that certain effects, like taste disturbance and severe hepatic dysfunction, may be noted early in the course of oral treatment, as defined in regulatory documentation.

Overdose and Emergency Response

Taficen Overdose and When to Seek Help

An overdose of Taficen (Terbinafine Hydrochloride) may present with documented clinical manifestations that include headache, dizziness, nausea, vomiting, abdominal pain, rash, and increased urination.


Documented Severe Outcomes

Ingestion of doses exceeding the standard therapeutic regimen carries a risk of severe, life-threatening systemic organ toxicity. This includes documented outcomes such as liver failure, which has been linked to the need for transplant or death, and severe neutropenia. Serious dermatologic reactions, including Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), are also official concerns. The severity of hepatic events may be exacerbated in individuals with pre-existing active or chronic liver disease.


Emergency Action and Management

Regulatory authorities mandate that immediate medical attention must be sought for any suspected overdose. Emergency services must be contacted if the exposed individual collapses, has a seizure, experiences difficulty breathing, or cannot be awakened. Treatment is directed toward symptomatic and supportive management, as no specific antidote is known. Procedures may include the administration of activated charcoal. Continuous observation and immediate evaluation of liver function tests are required due to the risk of severe complications.

Therapeutic Uses of Taficen

What Taficen Treats: Main Uses and Benefits

Taficen is generally applied across domains where additional symptomatic support is needed. It helps to ease the discomfort associated with acute or disruptive episodes, supporting patients in maintaining a sense of stability during periods of heightened symptoms. The information below describes the contexts in which this supportive therapeutic benefit is generally applied.


Support for Acute and Episodic Symptom Patterns

Taficen is commonly used across conditions characterized by periods of heightened symptoms and often during phases when symptoms become more noticeable. It helps address symptom clusters that may become intense or disruptive—such as those creating noticeable functional strain or systemic discomfort—providing supportive relief when short-term symptomatic assistance is needed.

This approach supports the patient during difficult episodes by easing distress and may assist with maintaining functional stability.

Quick Fact: Used for managing Disruptive Symptom Clusters


Easing Systemic Discomfort and Functional Strain

Applied in areas where short-term symptom management is appropriate, Taficen is relevant for managing symptoms that interfere with daily comfort, particularly in conditions presenting with systemic or localized discomfort. It supports general well-being during symptomatic phases.

Therapeutic Domains: Taficen is commonly used to help with managing symptoms that create noticeable physiological strain and is relevant in conditions characterized by episodic or fluctuating manifestations.

Eligibility and Restrictions for Use

The eligibility for Taficen (Terbinafine Hydrochloride) is strictly defined by regulatory authorities based on pre-existing health conditions, age, and physiological status.

Contraindications and Absolute Exclusions

The medicine is contraindicated and must not be used by individuals with a known history of hypersensitivity to Terbinafine or any of its components. It is also an absolute regulatory exclusion for patients with active or chronic liver disease.

Use Restrictions and Conditional Status

Use is not recommended for patients with severe renal impairment (creatinine clearance le 50 mL/min), which necessitates careful evaluation of organ function. Taficen is contraindicated for women who are breastfeeding as the active substance is known to pass into breast milk, and its use is generally not recommended during pregnancy.

Age and Comorbidity Rules

Eligibility for systemic use is primarily established in adults. The use of oral Taficen in the pediatric population is restricted, often requiring minimum age and weight thresholds, and is generally not established for infants. Regulators advise caution in patients with pre-existing conditions like Psoriasis or Lupus Erythematosus, due to the potential for disease exacerbation.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Taficen Oral Tablets are associated with officially documented drug-drug interactions that are primarily metabolic, involving the cytochrome P450 (CYP) enzyme system.

Official Exposure-Modifying Interactions

Interacting Substance Taficen's Effect on Co-administered Drug (Oral) Effect on Taficen Clearance (Oral)
Desipramine (a CYP2D6 substrate) Clearance is decreased, significantly increasing exposure. N/A
Caffeine Clearance is decreased by 19%. N/A
Cyclosporine Clearance is increased by 15%. N/A
Cimetidine (CYP inhibitor) N/A Clearance is decreased by 33%.
Rifampin (CYP inducer) N/A Clearance is increased by 100%.

Regulatory-Based Interaction Notes

Taficen is documented as an inhibitor of the CYP2D6 isozyme, a classification that underlies the risk of increased plasma concentrations for co-administered medicines metabolized by this enzyme.

Specific restrictions regarding patient status are formally stated. The oral tablet form is contraindicated in patients with chronic or active liver disease due to altered clearance and potential accumulation risk. Furthermore, the use of oral tablets is not recommended for patients with severe renal impairment (Creatinine Clearance le 50 mL/min).

In contrast, the topical formulations (cream, gel, solution) are officially noted to have no known drug interactions due to the very low systemic absorption of the active ingredient. The bioavailability of the oral tablet form is similar regardless of food intake.

Mechanism of Action

Taficen (Terbinafine) operates through a specific interruption of the fungal cell’s core metabolic processes, resulting in cell lysis and death. The mechanism results in a preferential effect on the pathogen.

Targeted Inhibition of Fungal Sterol Synthesis

The drug acts as a non-competitive inhibitor of squalene epoxidase (SQLE), an enzyme essential for creating ergosterol in fungal membranes. This primary molecular interaction halts the sterol biosynthesis pathway.

Dual Cascade Leading to Fungicidal Action

By blocking SQLE, the drug simultaneously causes a severe deficiency of ergosterol and a poisonous accumulation of squalene within the fungal cell membrane and cytoplasm. The combination of membrane weakening from sterol depletion and internal toxicity from squalene buildup results in the breakdown of the fungal cell structure and function (fungicidal action). This mechanism drives the fungicidal effect required for pathogen clearance from the tissues.

Selective Delivery to Keratin-Rich Sites

Terbinafine's high lipophilicity allows it to preferentially partition into and persist within keratin-rich tissues (skin, nails, hair) where dermatophytes reside. This characteristic is a kinetic mechanism that results in a sustained concentration of the drug at the pathogen’s site of infection, contributing to the fungicidal effect.

Dosage and Administration Information

How Taficen is Used

The usage of Taficen (Terbinafine Hydrochloride) is determined by its approved route of administration—either oral for systemic treatment or topical for local application to the skin or nails. The product is available as an oral tablet, oral granules, and various 1% topical preparations (cream, gel, solution).


Official Dosing and Regimen

The standard dosing regimen for oral use is 250 mg once daily. The required duration of treatment is fixed based on the infection site, not symptom severity, and must be adhered to for the full course:

Infection Site (Oral Tablet) Standard Adult Dose Treatment Duration
Fingernail Onychomycosis 250 mg once daily 6 weeks
Toenail Onychomycosis 250 mg once daily 12 weeks

Topical forms are generally applied once or twice daily, with durations varying according to the specific indication and formulation.


Administration Requirements

Specific instructions govern the intake conditions to ensure proper use following established protocols.

  • Oral Tablets: May be taken with or without food as the absorption is similar.
  • Oral Granules: Must be administered with food (e.g., pudding, mashed potatoes) and swallowed immediately without chewing; non-acidic foods must be used.
  • Topical Forms: Are for external use only and must not contact the eyes or other mucous membranes.

Population-Specific Considerations

Specific considerations apply to certain populations:

  • Hepatic Impairment: Use of oral Taficen is generally not recommended in patients with chronic or active liver disease.
  • Pediatric Dosing: Oral granule dosage is weight-based for children over 4 years of age.

Recent Clinical Evidence

Research evidence / Overview of studies for Taficen (Terbinafine Hydrochloride)


Evidence for Use in Fungal Nail Infection (Onychomycosis)

The research exploring Taficen's use in onychomycosis, a fungal nail infection, primarily relies on Randomized Controlled Trials (RCTs) and reviews of those trials in adult populations with confirmed dermatophyte infection. Researchers monitored measurements related to the physical state of the nail, including both the status of the fungus (mycological assessment) and the visible characteristics of the nail (clinical features). Studies reported measurements of mycological clearance or clinical response following defined treatment periods. What remains uncertain is the long-term characterization of outcomes in all populations. Data for certain groups, such as children or adults with significant co-existing health conditions, remain insufficient for drawing broad conclusions.


Evidence for Use in Athlete's Foot and Ringworm (Tinea Infections)

Research examined both topical and oral formulations of Taficen for common fungal skin conditions like athlete's foot (Tinea pedis), jock itch (Tinea cruris), and ringworm (Tinea corporis). Studies explored short-term symptom changes, focusing on episodes characterized by heightened symptom activity. These trials measured outcomes related to physical discomfort and outcomes linked to irritative states, such as scaling and itching. Studies report how symptoms evolved in the observed populations, documenting measurements of mycological assessment and symptom resolution across short treatment and follow-up intervals. The existing research provides context but not individual predictions, as the evidence quality varies across studies, especially for long-term outcomes.


Long-Term Studies and Durability of Follow-Up

Studies have explored long-term outcomes, particularly for oral use in onychomycosis, tracking patients for extended periods, sometimes up to five years, following the end of the treatment course. These long-term settings tracked patient-reported outcomes describing perceived discomfort. Studies monitored the status of the mycological assessment and recurrence of symptoms after patients completed their regimen. Despite the extended observation, long-term effects are not fully established across all studies, and certainty remains low regarding the exact recurrence rates, as these can be influenced by new infections and subject variability.

Key Studies & References Clinical Efficacy and Tolerability of Terbinafine 1% Cream in Patients with Pityriasis Versicolor

Frequently Asked Questions (FAQ)

Common questions about Taficen (FAQ)

Q: Is Taficen a strong medication compared to other treatments?

A: Official documents confirm that Taficen is classified as a potent antifungal agent. The medication is noted for its fungicidal action, which means it actively works to kill fungal cells, rather than just stopping their growth. This mechanism drives its therapeutic use.


Q: Are there any common foods or drinks that should be avoided while taking Taficen?

A: According to the official product information, there are no specific foods or common drinks that are required to be avoided while taking the tablets. However, the medicine has been shown to increase the effects of caffeine by decreasing how quickly the body clears it. Patients are generally advised to discuss all concomitant intake with their prescribing clinician.


Q: Can you drive or operate machinery if you are taking Taficen?

A: The official labeling lists side effects such as dizziness and fatigue as common adverse effects. Patients experiencing these symptoms are generally advised to avoid driving or operating machinery, as these effects may potentially impair safe performance.


Q: Is Taficen known to cause any long-term health problems?

A: Regulatory documents include warnings for rare but serious long-term concerns. These include severe liver injury (which can progress to liver failure) and a persistent loss or change in taste. Healthcare professionals may assess and monitor organ function, particularly the liver, during treatment.


Q: What is the typical time frame for re-evaluating Taficen use?

A: For infections like those affecting the nails, the full success of treatment is typically not visible until several weeks or months after the fixed treatment course is completed. This delay is due to the natural rate at which healthy nail tissue needs to grow out.


Q: Is Taficen meant to be taken temporarily or indefinitely?

A: The medication is prescribed for finite treatment durations that are predetermined based on the type and location of the infection being treated. Official documents indicate it is not intended for indefinite use.


Q: How long does it typically take to start feeling the effects of Taficen?

A: For fungal skin infections, patients may start to see an improvement in symptoms within about two weeks. However, for nail infections, the full clinical response may not be visible for several months because the active medicine needs time to be incorporated into the growing nail.


Q: Can Taficen be taken with regular vitamins or supplements?

A: Official interaction data focuses primarily on prescription drugs. Generally, there is not enough information to definitively confirm the safety of taking all non-prescription vitamins or supplements simultaneously.


Q: Is Taficen safe for older adults to use?

A: Official documents state there is no evidence to suggest that older adults require different dosages than younger patients. However, caution is advised, and pre-existing kidney or liver impairment is typically assessed before use.


Q: Is Taficen considered a 'cure' for the condition it treats?

A: The official goal of treatment is to achieve mycological cure (clearance of the fungus) and complete resolution of the signs and symptoms. This is the therapeutic endpoint expected when the drug works as intended.


Q: Why do people say Taficen made them gain weight?

A: Weight gain is not documented as a common or official adverse reaction in regulatory safety summaries. In contrast, a decrease in appetite, which sometimes resulted in weight loss, has been reported in very rare cases.


Q: Does Taficen affect blood pressure or heart rate?

A: Official safety information does not list blood pressure changes as a common effect. However, increased heart rate (tachycardia) and chest pain have been reported in rare cases.


Q: What happens if I forget to take a dose of Taficen?

A: The official product information contains specific guidance for missed doses. It generally instructs the patient to maintain the regular dosing schedule and not to double the dose. Consult the Patient Information Leaflet for detailed guidance.


Q: Is it true that Taficen is habit-forming?

A: Regulatory reviews confirm there is no known potential for producing withdrawal symptoms, and no cases of dependence or abuse have been documented in official records for this antifungal medication.


Q: Is there a generic version of Taficen available?

A: Yes, the active ingredient, which is terbinafine, is available as a generic medication. This is the standard term for the non-brand version of the drug.


Q: Does taking Taficen affect the results of common lab tests?

A: Yes, common laboratory tests may show changes, as clinically relevant elevations of liver enzymes (like ALT and AST) are a documented side effect that requires monitoring during treatment. This is often why a healthcare professional may recommend laboratory tests before and during the course of treatment.


Q: How long do the effects of one dose of Taficen last?

A: The active substance has a half-life of approximately 17 hours for the initial elimination phase. However, due to its accumulation in the body's tissues, it takes approximately 3 weeks to clear completely from the system.


Q: Why is Taficen only available by prescription?

A: Official documents restrict oral Taficen to prescription use because of the potential for serious adverse effects, especially concerning the liver and blood count. These risks require ongoing medical supervision and monitoring, which cannot be provided for an over-the-counter medicine.


Q: Are there any restrictions on activity while using Taficen?

A: Yes, patients are advised to minimize exposure to natural and artificial sunlight (such as tanning beds). This is because the medication can cause the skin to be highly sensitive to the sun, leading to photosensitivity reactions.


Q: Is Taficen safe to take while drinking a small amount of alcohol?

A: While general guidance suggests alcohol consumption is usually permissible, patients must be aware that the medication carries a risk of liver toxicity. This potential liver issue may require careful consideration if combined with alcohol use.


Q: How quickly does Taficen leave the body after you stop taking it?

A: The active substance is eliminated from the body slowly due to its accumulation in tissues. It has a terminal half-life of approximately 3 weeks as it gradually clears from the system.


Q: Is it normal to feel a bit nauseous when first starting Taficen?

A: Yes, nausea and a general upset stomach are documented as common gastrointestinal side effects. These effects may be more noticeable when first beginning the course of treatment.


Q: Has Taficen been recalled or had any major safety warnings?

A: Official labeling includes several serious warnings for rare but severe events. These include fatal liver failure, severe blood disorders, and life-threatening skin reactions (like Stevens-Johnson syndrome).


Q: Is it possible to become resistant to the effects of Taficen over time?

A: Official documents acknowledge that while the drug is highly effective, there is documented evidence of some fungal organisms developing in-vitro resistance to the active ingredient. This means the fungus may be less susceptible to the medicine over time.


Q: Can I take Taficen if I am currently taking herbal remedies?

A: Official interaction data focuses primarily on prescription drugs. Generally, there is not enough information to definitively state the safety of combining Taficen with herbal remedies, as these are not routinely tested for drug interactions.


Q: Does Taficen help with anxiety or difficulty sleeping?

A: The documented purpose of the drug is strictly to treat fungal infections. However, official adverse event listings do include psychiatric side effects such as insomnia (difficulty sleeping), depression, and anxiety.


Q: Are there any known interactions between Taficen and birth control pills?

A: Yes, menstrual disturbances (such as irregular cycles or breakthrough bleeding) have been reported in patients using oral Taficen concurrently with combined hormonal contraceptives. A healthcare professional can provide guidance on managing this potential effect.


Q: Does Taficen need to be taken at a specific time of day?

A: The tablets are prescribed to be taken once daily. To help maintain a consistent level of medicine in the body, they should preferably be taken at the same time each day, regardless of whether you take them with food or not.


Q: Can men and women use Taficen for the same condition?

A: Yes, the drug is indicated for use in the general adult population (both men and women) for the approved conditions. Specific precautions are only given for women who are pregnant or breastfeeding.


Q: Does Taficen interact with common pain relievers like ibuprofen?

A: Official information states that common over-the-counter pain relievers such as ibuprofen, paracetamol, and naproxen are generally considered safe to take with Taficen. However, interactions are known with other prescription pain medications.


Q: Does Taficen interact with common cold or flu medicines?

A: Taficen is known to affect how the body processes certain drugs through the CYP2D6 enzyme. This may mean that the drug can potentially increase the effects of some cold or flu medicines that are metabolized by this enzyme.

How should Taficen be stored and disposed of?

How to Store and Dispose of Taficen

Official regulations define strict storage and disposal requirements for Taficen (terbinafine hydrochloride) to maintain product stability.


Storage Requirements

Feature Oral Tablets Topical Cream
Temperature Store at controlled room temperature (20 C to 25 C) Store at controlled room temperature (20 C to 25 C)
Container Keep in a tightly closed container Keep tube tightly closed in the original container
Protection Keep away from light and excess moisture Do not freeze and protect from light

Stability and Disposal

Topical cream has an in-use stability period and must be discarded 28 days after first opening. All forms of Taficen must be kept out of reach of children for safety. Disposal of any unused or expired product must be done in accordance with local requirements for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Taficen found in:

A-Z Index: